Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine

Learn more about:
Related Clinical Trial
Administration of Kisspeptin to Subjects With Reproductive Disorders The Luveris In Vitro Fertilization Trial A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Pituitary Function and Spontaneous Intracranial Hypotension Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility Aripiprazole and Prolactin Study Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Characterization of Macroprolactinemia Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) Endometriosis Patients Undergoing Quinagolide Treatment Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire Hyperprolactinemia and Adrenal Steroidogenesis Administration of Kisspeptin in Patients With Hyperprolactinemia Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

Brief Title

Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine

Official Title

Therapy With Bromocriptine in Patients With Symptomatic Risperidone-Induced Hyperprolactinemia

Brief Summary

      Antipsychotic drugs can cause a clinically relevant hyperprolactinemia due to blocking the
      dopamine receptors in the pituitary.Schizophrenic patients suffering from a
      neuroleptic-induced hyperprolactinemia will be examined endocrinologically. Adverse drug
      effects and diagnoses will be confirmed by measuring hormones.
    

Detailed Description

      Antipsychotic drugs can cause a clinically relevant hyperprolactinemia due to blocking the
      dopamine receptors in the pituitary.Depending on its concentration hyperprolactinemia causes
      a median hypogonadism with estrogen insufficiency in women and testosterone insufficiency in
      men by inhibiting the pulsatile GnRH-secretion.The hyperprolactinemia-induced symptoms have
      been successfully medicated for years with dopamine agonists like bromocriptine.

      In patients with psychiatric diseases hyperprolactinemia is usually not treated with dopamine
      agonist fearing a reexacerbation of the underline psychiatric disease. In a few studies and
      casuistically the treatment of neuroleptic-induced hyperprolactinemia with bromocriptine has
      been shown to be effective without causing reexacerbation of psychotic symptoms.

      Schizophrenic patients suffering from a neuroleptic-induced hyperprolactinemia (in extremis
      galactorrhoea and amenorrhoea. in women, loss of libido and erectile dysfunction in men) will
      be examined endocrinologically. Adverse drug effects and diagnoses will be confirmed by
      measuring hormones (prolactin, LH, FSH, testosterone, estradiol). In case of a clear
      symptomatic, neuroleptic-induced hyperprolactinemia patients will be medicated with
      bromocriptin. Therapeutical success will be determined endocrinologically in week 0, 1, 2, 3,
      4, 8, 12, 16, 20 and 24 together with a psychiatric examination (PANSS, HAM-D, Simpson-Angus
      Scale (SAS)). Safety of therapy will be ensured by the close meshed psychiatric examinations.
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Prolactin

Secondary Outcome

 PANSS

Condition

Schizophrenia

Intervention

Bromocriptin


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

20

Start Date

May 2006

Completion Date

May 2008


Eligibility Criteria

        Inclusion Criteria:

          -  Female and male schizophrenic patients.

          -  Antipsychotic treatment with risperidone.

          -  Diagnosis of a clinically relevant hyperprolactinemia.

          -  No indication of disturbance of the somato-, cortico or thyreotropic hypophysis-axis
             (IGF-1, cortisol, ACTH, TSH, FT3, FT4)

        Exclusion Criteria:

          -  Severe somatic disease, especially coronary disease.

          -  Acute psychotic exacerbation.

          -  Pregnancy
      

Gender

Male

Ages

18 Years - 60 Years

Accepts Healthy Volunteers

No

Contacts

Wolfgang Maier, MD, 0049-(0)228-287-5681, [email protected]

Location Countries

Germany

Location Countries

Germany

Administrative Informations


NCT ID

NCT00315081

Organization ID

150-05



Study Sponsor

University Hospital, Bonn


Study Sponsor

Wolfgang Maier, MD, Principal Investigator, University of Bonn, Department of Psychiatry


Verification Date

November 2005